Merck & Co. (MRK) : Cordasco Financial Network reduced its stake in Merck & Co. by 23.01% during the most recent quarter end. The investment management company now holds a total of 28,126 shares of Merck & Co. which is valued at $1,542,430 after selling 8,407 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Apr 25, 2016.Merck & Co. makes up approximately 1.71% of Cordasco Financial Network’s portfolio.
Merck & Co. opened for trading at $54.85 and hit $55.36 on the upside on Monday, eventually ending the session at $55.3, with a gain of 0.84% or 0.46 points. The heightened volatility saw the trading volume jump to 96,78,915 shares. Company has a market cap of $153,472 M.
Other Hedge Funds, Including , Mathes Company reduced its stake in MRK by selling 935 shares or 3.29% in the most recent quarter. The Hedge Fund company now holds 27,452 shares of MRK which is valued at $1,505,468. Merck & Co. makes up approx 0.90% of Mathes Company’s portfolio.Bridges Investment Management Inc reduced its stake in MRK by selling 1,331 shares or 4.72% in the most recent quarter. The Hedge Fund company now holds 26,882 shares of MRK which is valued at $1,525,285. Merck & Co. makes up approx 0.27% of Bridges Investment Management Inc’s portfolio.Stralem Co Inc reduced its stake in MRK by selling 42,946 shares or 8.26% in the most recent quarter. The Hedge Fund company now holds 476,747 shares of MRK which is valued at $27,050,625. Merck & Co. makes up approx 2.91% of Stralem Co Inc’s portfolio.Gradient Investments boosted its stake in MRK in the latest quarter, The investment management firm added 2,411 additional shares and now holds a total of 68,024 shares of Merck & Co. which is valued at $3,818,867. Merck & Co. makes up approx 0.47% of Gradient Investments’s portfolio.Integrated Investment Consultants boosted its stake in MRK in the latest quarter, The investment management firm added 61 additional shares and now holds a total of 31,386 shares of Merck & Co. which is valued at $1,762,010. Merck & Co. makes up approx 1.00% of Integrated Investment Consultants’s portfolio.
On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 3, 2016. Analyst had a consensus of $0.91. The company had revenue of $10215.00 million for the quarter, compared to analysts expectations of $10355.20 million. The company’s revenue was down -2.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.87 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.Merck & Co. was Downgraded by BofA/Merrill to ” Neutral” on Jan 27, 2016.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.